1. Scrip
  2. >>Focus On Asia

Chinese Newcomers Look For Niche Immuno-Oncology Opportunities

Cervical Cancer, SCLC Eyed

 
• By Dexter Jie Yan

Chinese pharma companies are continuing to pile into the already overcrowded domestic anti-PD-1/L1 sector in China, but despite the competition and regulatory tightening, the latecomers are looking for opportunities in areas such as cervical and small cell lung cancer with relatively fewer contenders.

niche market
Latecomers target niche markets in China PD-1/L1 race • Source: Shutterstock

Major Chinese drug makers are continuing to leap into the fray of the already packed PD-1/L1 class of agents. While China’s regulator signalled a tightening of reviews for immuno-oncology therapies in 2021, the latecomers are betting that certain indications will be less crowded.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from China

More from Focus On Asia